F3 has licensed the following Patents from the University of Chicago:
- Two granted U.S. patents
- One granted European patent (validated in Germany, France, UK, Belgium, Turkey, Greece, Hungary, Poland, Spain, the Netherlands, Italy)
- Pending IP across multiple indications
- Fifteen Pending U.S. patents
Guided by the extensive research of our Scientific Advisory Team, F3 has secured a meaningful IP portfolio to bring the AmiGuard platform to market globally across a broad array of indications and formulations.